Market Overview

UPDATE: Tigress Initiates Coverage On Illumina

Share:
Related ILMN
Biotech Short-Sellers Prefer Amgen To Gilead Sciences
Benzinga's Top Upgrades

In a report released Friday, Tigress analyst Philip Van Deusen initiated coverage on Illumina (NASDAQ: ILMN) with a Buy rating.

Analysts at Tigress favor Illumina for reducing costs in its genomic health progress with its genetic testing, diagnosis and individualized treatment. Illumina's development of hardware will strengthen, influencing an increase to barriers to entry. Tigress holds high expectations for Illumina sequencing machines, growing 51 percent year over year and making a majority of the company's revenue.

Latest Ratings for ILMN

DateFirmActionFromTo
May 2015Morgan StanleyUpgradesEqual-weightOverweight
Apr 2015Tigress FinancialUpgradesBuyStrong Buy
Apr 2015CitigroupMaintainsBuy

View More Analyst Ratings for ILMN
View the Latest Analyst Ratings

Posted-In: Philip Van Deusen TigressInitiation Analyst Ratings

 

Related Articles (ILMN)

Around the Web, We're Loving...

Get Benzinga's Newsletters